Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.
about
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationApplication of radiation technology in vaccines developmentTargeted anti-vascular therapies for ovarian cancer: current evidenceFirst-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.Cardiovascular toxicities from systemic breast cancer therapy.Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study.Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysisRisks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysisUse of bevacizumab as a first-line treatment for metastatic breast cancer.Weighed, measured, and still searching: bevacizumab in the treatment of unselected patients with advanced breast cancerA phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.Targeting angiogenesis in metastatic breast cancerBevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available EvidenceCardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients.A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.RAS interaction with PI3K p110α is required for tumor-induced angiogenesis.Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancer.Targeting VEGF-A with a vaccine decreases inflammation and joint destruction in experimental arthritis.Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience.
P2860
Q24193614-F18CEC41-9341-40BD-AA63-39D47C4E72FEQ26798165-880E1F43-AFC0-4CDC-A7F1-521C33919253Q26830287-D39B72FD-9F97-40B5-A80A-00C6734DBDA3Q30657829-43ABA5F5-AA9D-4D46-82AF-7730A682F07DQ31060162-525E9083-511B-455E-85D3-BF7C7ECC091FQ31152878-69A007B0-0C59-400D-9872-8C779EEF1D9CQ31157714-E265BD23-7C7F-460B-A6A3-356A64019C76Q34630349-D741D2C4-D8DD-4210-87D6-9F714572ED4CQ34732915-8563196F-9AF4-4482-9F5B-7B3864FB86A6Q35064031-5F7D2F51-63DC-4B89-9806-863167BBCFACQ35118673-66D726EB-36AD-407F-9C4D-3B8A527D9FADQ35445151-FA6E3DDF-A996-4926-813A-0BB4E0167236Q35642338-FB9512B1-AFAE-4F29-BACB-AD1A44AA5D65Q36163040-CF6CCB5C-21DF-4BB5-A029-A821700F3AF3Q36182795-18424F82-5D34-4F92-92CC-BFD81DCDB8F5Q36248498-FAE773D6-DBF7-4264-AA21-35C7264CE395Q38371293-F009CEE5-CCE9-474F-984B-C20D83D3146CQ38839151-AF9F451B-2BFA-4D5B-B869-808F44F7A52DQ38977239-047665E3-B6DA-48F7-9A16-92885C64884BQ39204706-45CCAE1F-71F8-46F6-8DB2-6FEF71DBD627Q40485583-B2D5C1E8-CDBA-4EE8-8A63-8FBF471B0B80Q42908395-C99204FB-693E-49AD-89F9-D65C0B90D142Q50204127-F286A255-5280-4260-9185-6333080ABC84Q54459895-1EC9A119-0C59-4EEE-A96A-4BDD58DB06F5
P2860
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Adverse events risk associated ...... chemotherapy: a meta-analysis.
@en
Adverse events risk associated ...... chemotherapy: a meta-analysis.
@nl
type
label
Adverse events risk associated ...... chemotherapy: a meta-analysis.
@en
Adverse events risk associated ...... chemotherapy: a meta-analysis.
@nl
prefLabel
Adverse events risk associated ...... chemotherapy: a meta-analysis.
@en
Adverse events risk associated ...... chemotherapy: a meta-analysis.
@nl
P2093
P50
P921
P356
P1433
P1476
Adverse events risk associated ...... chemotherapy: a meta-analysis.
@en
P2093
A González-Martín
A Llombart
J O'Shaughnessy
N Ramírez-Merino
P304
P356
10.1093/ANNONC/MDR432
P577
2011-10-04T00:00:00Z